Sónia Moreira

Sónia Moreira

Auto-generated profile, based on publicly available information

Sónia Moreira

Department of Internal Medicine, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Inês Maria dos Santos GuerraInês Maria dos Santos Guerra
Inês Maria dos Santos Guerra
Helena FerreiraHelena Ferreira
Helena Ferreira
TMTânia Melo
Tânia Melo
HRHugo Rocha
Hugo Rocha
SMSónia Moreira
Sónia Moreira
Ana Sofia Pereira MoreiraAna Sofia Pereira Moreira
Ana Sofia Pereira Moreira
Fatty acid oxidation disorders (FAODs) are inborn errors of metabolism (IEMs) caused by defects in the fatty acid (FA) mitochondrial β-oxidation. The most common FAODs are characterized by the accumulation of medium-chain FAs and long-chain (3-hydroxy) FAs (and their carnitine derivatives), respectively. These deregulations are associated with lipotoxicity which affects several organs and potentially leads to life-threatening complications and comorbidities. Changes in the lipidome have been associated with several diseases, including some IEMs. In FAODs, the alteration of acylcarnitines (CARs) and FA profiles have been reported in patients and animal models, but changes in polar and neutral lipid profile are still scarcely studied. In this review, we present the main findings on FA and CAR profile changes associated with FAOD pathogenesis, their correlation with oxidative damage, and the consequent disturbance of mitochondrial homeostasis. Moreover, alterations in polar and neutral lipid classes and lipid species identified so far and their possible role in FAODs are discussed. We highlight the need of mass-spectrometry-based lipidomic studies to understand (epi)lipidome remodelling in FAODs, thus allowing to elucidate the pathophysiology and the identification of possible biomarkers for disease prognosis and an evaluation of therapeutic efficacy.

28 November 2017 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SMSónia Moreira
Sónia Moreira
BCBernardo Cunha
Bernardo Cunha
NJNelson Pedro Jesus
Nelson Pedro Jesus
LSLèlita Santos
Lèlita Santos
Camurati-Engelmann disease (CED) is a rare disorder included in the group of craniotubular hyperostosis diseases. Corticosteroids are used for pain management in CED, but in refractory or corticosteroid-non-tolerant patients, pain management is limited. We report the case of a woman with CED diagnosed in early infancy whose initial complaints included persistent bone pain associated with progressive functional disability. She was treated with steroids but over time became dependent on higher doses with only mild pain relief. In her third decade, she was diagnosed with ulcerative colitis (UC) and was treated with mesalazine, azathioprine and prednisolone. Due to recurrent exacerbations of UC, treatment was changed to infliximab, an antitumour necrosis factor-alpha (TNFα). Remission of UC was achieved and CED-associated pain also improved with infliximab. This is the first report showing a possible role of anti-TNFα in pain management in CED with unsatisfactory response to steroids.

1 March 2021 in European Geriatric Medicine
Verified
Journal Article
Closed access
PDF file
SMSónia Bastos Moreira
Sónia Bastos Moreira
JBJoão Pedro Baptista
João Pedro Baptista
JGJoão Gonçalves-Pereira
João Gonçalves-Pereira
JPJosé Manuel Pereira
José Manuel Pereira
OROrquídea Ribeiro
Orquídea Ribeiro
JPJosé-Artur Paiva
José-Artur Paiva

2 November 2023 in Acta Medica Portuguesa
Verified
Journal Article
Open access
PDF file
LALuís Brito Avô
Luís Brito Avô
LPLuísa Pereira
Luísa Pereira
AOAnabela Oliveira
Anabela Oliveira
FFFilipa Ferreira
Filipa Ferreira
PFPaulo Filipe
Paulo Filipe
SMSónia Moreira
Sónia Moreira
Acute porphyrias are a group of rare genetic metabolic disorders, caused by a defect in one of the enzymes involved in the heme biosynthesis, which results in an abnormally high accumulation of toxic intermediates. Acute porphyrias are characterized by potentially life-threatening attacks and, for some patients, by chronic manifestations that negatively impact daily functioning and quality of life. Clinical manifestations include a nonspecific set of gastrointestinal, neuropsychiatric, and/or cutaneous symptoms. Effective diagnostic methods are widely available, but due to their clinical heterogeneity and non-specificity, many years often elapse from symptom onset to diagnosis of acute porphyrias, delaying the treatment and increasing morbidity. Therefore, increased awareness of acute porphyrias among healthcare professionals is paramount to reducing disease burden. Treatment of acute porphyrias is centered on eliminating the potential precipitants, symptomatic treatment, and suppressing the hepatic heme pathway, through the administration of hemin or givosiran. Moreover, properly monitoring patients with acute porphyrias and their relatives is fundamental to preventing acute attacks, hospitalization, and long-term complications. Considering this, a multidisciplinary panel elaborated a consensus paper, aiming to provide guidance for an efficient and timely diagnosis of acute porphyrias, and evidence-based recommendations for treating and monitoring patients and their families in Portugal. To this end, all authors exhaustively reviewed and discussed the current scientific evidence on acute porphyrias available in the literature, between November 2022 and May 2023.

18 December 2024 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
ARAna Rita Ramalho
Ana Rita Ramalho
SMSónia Moreira
Sónia Moreira
LRLina C. Ramos
Lina C. Ramos
JMJosé Pereira de Moura
José Pereira de Moura

15 June 2018 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SMSónia Moreira
Sónia Moreira
JCJorge Crespo
Jorge Crespo
LSLèlita Santos
Lèlita Santos
Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterised by vascular abnormalities, immune system activation and fibrosis. Lymphatic involvement in SSc was described more recently and starts in early stages. This report describes a 46-year-old patient who developed over the last 2 years asymmetric lymphedema in lower extremities. Compromise in lymphatic drainage was confirmed by lymphoscintigraphy. She also presented Raynaud’s phenomenon, a scleroderma pattern in nailfold capillaroscopy, cutaneous thickening and anticentromere antibodies, which together resulted in a new diagnosis of limited cutaneous SSc. Treatment with methotrexate, prednisolone and lymphatic drainage resulted in lymphedema improvement. To our knowledge, this is the first case of grade 2 lymphedema in the setting of anticentromere-positive limited cutaneous SSc. We highlight the importance of considering rheumatic diseases in the differential diagnosis of lymphedema.